Wulff-Burchfield, Elizabeth Marie http://orcid.org/0000-0003-1474-7095
Potts, Maryellen
Glavin, Katherine
Mirza, Moben
Funding for this research was provided by:
School of Medicine, University of Kansas
Article History
Received: 30 October 2020
Accepted: 18 February 2021
First Online: 4 March 2021
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This research was approved by the Institutional Review Board of the University of Kansas Cancer Center (#145269).
: All study participants provided voluntary and verbal informed consent prior to participating in the study; the institutional review board designated this study as minimal risk, and therefore verbal informed consent was deemed permissible.
: All study participants provided voluntary and verbal informed consent for publication; the institutional review board designated this study as minimal risk, and therefore verbal informed consent was deemed permissible.
: Dr. Wulff-Burchfield: consultative or advisory role – Exelixis, Astellas; family member with stock ownership – Immunomedics, Nektar. All relationships are outside of the submitted work.Dr. Potts: No relationships to discloseMs. Glavin: No relationships to discloseDr. Mirza: No relationships to disclose